HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dramatic improvement of myotonia permanens with flecainide: a two-case report of a possible bench-to-bedside pharmacogenetics strategy.

AuthorsJean-François Desaphy, Anna Modoni, Mauro Lomonaco, Diana Conte Camerino
JournalEuropean journal of clinical pharmacology (Eur J Clin Pharmacol) Vol. 69 Issue 4 Pg. 1037-9 (Apr 2013) ISSN: 1432-1041 [Electronic] Germany
PMID23052413 (Publication Type: Case Reports, Letter, Research Support, Non-U.S. Gov't)
Chemical References
  • NAV1.4 Voltage-Gated Sodium Channel
  • Voltage-Gated Sodium Channel Blockers
  • Flecainide
Topics
  • Female
  • Flecainide (administration & dosage, therapeutic use)
  • Humans
  • Male
  • Mutation
  • Myotonia Congenita (drug therapy, genetics)
  • NAV1.4 Voltage-Gated Sodium Channel (genetics)
  • Nuclear Family
  • Pharmacogenetics
  • Treatment Outcome
  • Voltage-Gated Sodium Channel Blockers (administration & dosage, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: